Intelligence · Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring ≤24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.
-
US 7632502
Cell wall mannoproteins and active epitopes from Candida albicans and antibodies recognizing them
granted -
US 7632484
Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
granted -
US 7632814
HYD1 peptides as anti-cancer agents
granted -
US 7629380
Antitumor agents
granted -
US 7629308
Methods relating to muscle selective calcineurin interacting protein (MCIP)
granted -
US 7627938
Tapered hollow metallic microneedle array assembly and method of making and using the same
granted -
US 7625871
Indole antiviral compositions and methods
granted -
US 7625563
Cancer treatment methods using selected immunoconjugates for binding to aminophospholipids
granted -
US 7622130
Methods and compositions for the non-surgical removal of fat
granted -
US 7622107
Recombinant intracellular pathogen immunogenic compositions and methods for use
granted -
US 7622571
Methods and compositions for Mycoplasma pneumoniae exotoxins
granted -
US 7622549
Human telomerase reverse transcriptase polypeptides
granted -
US 7622118
Cancer treatment methods using selected antibodies to aminophospholipids
granted -
US 7618627
Method of increasing radiation sensitivity by inhibition of beta one integrin
granted -
US 7618630
Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
granted -
US 7618936
Methods for treating and diagnosing cancer with WNT inhibitory Factor-1 (WIF-1)
granted -
US 7619000
S-dimethylarsino-thiosuccinic acid S-dimethylarsino-2-thiobenzoic acid S-(dimethylarsino) glutathione as treatments for cancer
granted -
US 7615223
Selected immunoconjugates for binding to aminophospholipids
granted -
US 7615208
Metal ion-labeled bis-aminoethanethiol-targeting ligand conjugates, compositions, and methods for tissue-specific disease imaging
granted -
US 7615573
Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors
granted -
US 7612107
Treatment and inhibition of disease conditions using flexible heteroarotinoids
granted -
US 7611532
Coated implantable medical device
granted -
US 7611693
Mechanism-based targeted pancreatic beta cell imaging and therapy
granted -
US 7611533
Coated implantable medical device
granted -
US 7612188
Modified vitamin K. dependent polypeptides
granted -
US 7611704
Compositions and methods for treating viral infections using antibodies and immunoconjugates to aminophospholipids
granted -
US 7608272
Methods and compositions for vaccination of animals with PRRSV antigens with improved immunogenicity
granted -
US 7608449
Methods and compositions related to high-titer pseudotyped retroviruses
granted -
US 7608641
Creatine oral supplementation using creatine hydrochloride salt
granted -
US 7608683
Stress proteins and peptides and methods of use thereof
granted -
US 7604968
Microorganisms for the recombinant production of resveratrol and other flavonoids
granted -
US 7605131
EML4-ALK fusion gene
granted -
US 7604973
DNA encoding hyaluronan synthase from Pasteurella multocida and methods of use
granted -
US 7601731
Antimicrobial flush solutions
granted -
US 7601490
Development of influenza A antivirals
granted -
US 7601683
Protein conformational isomers, methods of making, methods for using, compositions comprising and products made therewith
granted -
US 7601802
Cysteine-containing peptides having antioxidant properties
granted -
US 7598048
Screening methods for identifying agents that modulate output of a circadian pacemaker
granted -
US 7598356
Method for purifying a protein of the cystine-knot superfamily
granted -
US 7598341
Molecules that selectively home to vasculature of premalignant or malignant lesions of the pancreas and other organs
granted -
US 7595431
Mouse models of human prostate cancer
granted -
US 7595060
Yeast-antigen compositions methods of making the same
granted -
US 7592016
Methods for preparing and using implantable substance delivery devices
granted -
US 7591995
Cobalamin conjugates useful as imaging and therapeutic agents
granted -
US 7588912
Compositions and methods for preventing and treating anthrax diseases
granted -
US 7585868
Substituted pyrazolo[3,4-D]pyrimidines as kinase antagonists
granted -
US 7585622
Increasing the proliferative capacity of cells using telomerase reverse transcriptase
granted -
US 7585842
Human kunitz-type inhibitor with enhanced antifibrinolytic activity
granted
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory